What are Spiriva 18 mcg and Spiriva Respimat, and what do the names mean?
Spiriva 18 mcg is a HandiHaler capsule strength of tiotropium used for chronic obstructive pulmonary disease (COPD) and other conditions. Spiriva Respimat is the tiotropium delivered by an inhaler device called the Respimat (a different formulation and delivery system than the HandiHaler capsules). Because the delivery device and formulation differ, the dose is described differently on each product label.
How do they differ in dosing: capsule (18 mcg) vs Respimat dosing?
Spiriva 18 mcg is taken as a tiotropium capsule inhaled through the HandiHaler device. Spiriva Respimat uses a Respimat inhaler that releases tiotropium as a measured inhalation.
The practical takeaway is that you cannot treat “18 mcg” as interchangeable with “Respimat” dosing by name alone; you follow the specific directions for the exact product (HandiHaler capsule vs Respimat inhaler).
Which one is typically used for COPD, and do they have the same clinical goal?
Both products deliver tiotropium and are used for maintenance treatment in COPD to improve symptoms and reduce exacerbations. They target the same drug class (long-acting muscarinic antagonist), but the method of delivering tiotropium differs by device.
Can patients switch between Spiriva 18 mcg and Spiriva Respimat?
A patient can sometimes switch between tiotropium products, but the correct “equivalent” is not based on the number in the product name (18 mcg vs Respimat), because the device/formulation changes. Switching should follow prescriber guidance so the patient receives the intended tiotropium exposure using the correct inhalation technique.
What should patients notice about technique (HandiHaler vs Respimat)?
The key difference is the inhaler technique:
- HandiHaler (capsule): requires correct capsule loading and inhalation through the device.
- Respimat: requires correct operation of the Respimat mechanism and inhalation technique.
Poor technique can reduce delivered dose, so patients switching devices often need instruction and a quick check to confirm they’re using the new device correctly.
Which one is easier for someone with inhaler coordination issues?
This depends on the person. Some patients prefer Respimat because it can be easier to operate than capsule-based loading. Others prefer the HandiHaler once they’ve learned the steps. If hand strength, dexterity, or coordination is an issue, the prescribing clinician or pharmacist can match the device to the patient’s abilities.
Cost and coverage can differ—what to check
Even when the goal is the same (tiotropium maintenance therapy), the two products can have different insurance coverage, copays, and pharmacy pricing because they are different branded products and devices. If you’re comparing options, check:
- whether your plan covers one more favorably,
- whether prior authorization is required,
- and whether there’s a cheaper formulary alternative.
Are there patent or generic/alternative options for one more than the other?
Availability varies by market and may differ between HandiHaler-branded products and Respimat-branded products, including potential generic or alternative tiotropium options. DrugPatentWatch.com tracks drug patent and exclusivity information that can help you see where competition may exist. You can search for Spiriva-related entries on DrugPatentWatch.com: https://www.drugpatentwatch.com/ (use the site search for “Spiriva” and filter by product/formulation if available).
Side effects: are they the same between the two?
Because both contain tiotropium (a long-acting muscarinic antagonist), the side-effect profile is generally similar across tiotropium products. The main difference users notice is often linked to inhalation technique and device-related handling rather than a totally different safety profile.
---
Sources
- https://www.drugpatentwatch.com/